EU MDR – Person Responsible for Regulatory Compliance (PRRC)
The EU Medical Devices Regulation (MDR) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices and accessories for such devices. When compared to the prior applicable Directives, the MDR (and also IVDR) makes it mandatory for manufacturers to have within their organizations at least one Person Responsible for Regulatory Compliance.

MDR, IVDR AND PRRC

In 2017, two Regulations on medical devices and in in vitro diagnostic medical devices entered into force in the European Union (EU), progressively replacing the 3 existing Directives. The main goal was to establish a modernized and more robust EU legislative framework and to safeguard a better public health protection and patient safety.

The EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices for human use (and accessories for such devices). The Regulation (EU) 2017/746 sets out the rules on in vitro diagnostic medical devices (IVDR).

According to Article 15 of both Regulations, it is mandatory for manufacturers to have, within their organization (as an employee), a person responsible for regulatory compliance (PRRC). Importers and Authorized Representatives must also have an PRRC. The PRRC must possess requisite expertise in the field of medical devices, which shall be demonstrated with one of the following qualifications:

  • Four years of professional experience in regulatory affairs or in quality management systems relating to medical devices;
  • Diploma, certificate (or other formal qualification) from a university degree in law, medicine, pharmacy, engineering or other relevant scientific discipline (recognized as equivalent by the Member State concerned) and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices.

If the qualification was obtained outside the EU it must be recognized by an EU Member State as equivalent to the EU corresponding qualification. The professional experience should be related to the EU requirements in the field.

The PRRC is responsible for the technical documentation, EU Declaration of Conformity (drawn up and kept up-to-date), post-market surveillance obligations and checking the conformity of devices before they are released (according to the quality management system implemented). Vigilance activities, recording and reporting incidents, safety and performance requirements, clinical investigations and performance studies are also among the responsibilities and roles of the PRRC.

Each legal manufacturer must have its own PRRC. The PRRC must be close to the manufacturer, which means that if the manufacturer is located in the EU, its PRRC must also be located in the EU.

When it comes to micro and small manufacturers, they may subcontract the responsibilities of a PRRC to a third party, but it must be available permanently and continuously to them. This is also the case for Authorized Representatives, who may also outsource this role. The PRRC of an Authorized Representative (AR) is responsible for ensuring that the tasks of the AR (as specified in the given mandate) are fulfilled.

An AR and a manufacturer established outside the EU cannot have the same PRRC, ensuring a higher level of scrutiny and that the supervision and control of the production of devices, post-market surveillance and vigilance activities are effectively performed. For the same purpose, the PRRC of a micro and small manufacturer and the PRRC of the AR of that same company shall not belong to the same external organization.

References:

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.
  2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices.
  3. MDCG 2019-7 – Guidance on Article 15 of the Medical Device Regulation (MDR) and in vitro Diagnostic Device Regulation (IVDR) regarding a “person responsible for regulatory compliance” (PRRC).

further
reading

cosmetic products

United Kingdom Restricts the Use of BHT in Cosmetic Products

The United Kingdom has taken a significant step in regulating the use of Butylated Hydroxytoluene (BHT) in cosmetic products. This move is crucial for distributors, manufacturers, and importers to ensure compliance and maintain the safety of their products in the UK market.

Read More »
cosmetic products

Great Britain Mandatory Classification List (MCL): cosmetic ingredients added.

On March 12, 2024, the Health and Safety Executive (HSE) updated the GB Mandatory Classification List (MCL) by adding 25 new chemical substances, as mandated by Article 37 of the GB Classification, Labelling and Packaging (CLP) Regulation. This update impacts substances identified as cosmetic ingredients with proposed Carcinogen, Mutagen, or Reprotoxic (CMR) classifications under Article 15 of the UK Cosmetics Regulation (UKCR). Notably, 2-ethylhexanoic acid and its zinc salt, along with Dimethyltolylamine, are among those facing potential bans and additions to the UK Cosmetics Regulation’s Annex II. These changes will come into effect on September 2, 2025.

Read More »
cosmetic products

New coating for TiO2 (nano) – is it safe?

The Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on new coating for Titanium Dioxide (nano). It declared the data was not enough to draw conclusions regarding the safety of this alternative coating, as more evidence of similarity to other nanomaterials is necessary.

Read More »
cosmetic products

New EU cosmetic restrictions on Cyclic Volatile Methyl Siloxanes (cVMS)

Cyclic volatile methyl siloxanes (cVMS) have raised environmental concerns because of their persistence and bioaccumulative properties. In light of these concerns, the European Union has extended restrictions on substances like D4, D5, and D6 in cosmetic products. New regulations will further limit the concentration of these compounds in both rinse-off and leave-on products, with compliance deadlines set for 2026 and 2027.

Read More »
cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »